BioSpace News Archive

Insulet Corporation announced plans to release its financial results for the fourth quarter and full year of 2022 on February 23, 2023 after the close of the financial markets.

Matinas BioPharma today announced a strategic collaboration with National Resilience, Inc.

Eyenovia, Inc. today announced positive results from a research study conducted in collaboration with Dr. Pedram Hamrah, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatment administered via Optejet versus latanoprost+BAK administered via standard eye drops.

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Siobhan Nolan Mangini, President and Chief Financial Officer, will participate in the B. Riley Securities 3rd Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 19th, at 11:00 am ET.

Inari Medical, Inc. today announced that the first patient has been enrolled in DEFIANCE, a prospective randomized controlled trial (“RCT”) comparing the clinical outcomes of patients with iliofemoral deep vein thrombosis (“DVT”) treated with the ClotTriever System versus anticoagulation only.

The Coalition for Epidemic Preparedness Innovations (CEPI) and Tiba Biotech , a preclinical biopharmaceutical company, today announced a new partnership agreement to evaluate Tiba Biotech’s next-generation RNA vaccine platform technology.

Dermavant to Present Data from Multiple Studies of VTAMA ® (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference.

Unlearn®, the only artificial intelligence (AI) company developing prognostic digital twins to run smaller, faster clinical trials, today announced that Arman Sabbaghi, Ph.D. has been appointed Head of Biostatistics Research.

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the completion of enrollment for the randomization phase in the pivotal phase 3 SPLASH trial, on schedule and meeting previous guidance.

DiaCarta, Ltd. (“DiaCarta”) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirusTM MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection.